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Implantable Loop Recorder Monitoring for Reﬁning Management of
Children With Inherited Arrhythmia Syndromes
Jennifer N. Avari Silva, MD, FHRS; Burt I. Bromberg, MD; Fredrick K. Emge, MD; Tammy M. Bowman, CNP; George F. Van Hare, MD, FHRS
Background-—Implantable loop recorders (ILRs) are conventionally utilized to elucidate the mechanism of atypical syncope. The
objective of this study was to assess the impact of these devices on management of pediatric patients with known or suspected
inherited arrhythmia syndromes.
Methods and Results-—A retrospective chart review was undertaken of all pediatric patients with known or suspected inherited
arrhythmia syndromes in whom an ILR was implanted from 2008 to 2015. Captured data included categorization of diagnosis,
treatment, transmitted tracings, and the impact of ILR tracings on management. Transmissions were categorized as symptomatic,
autotriggered, or routine. Actionable transmissions were abnormal tracings that directly resulted in a change of medical or device
therapy. A total of 20 patients met the stated inclusion criteria (long QT syndrome, n=8, catecholaminergic polymorphic ventricular
tachycardia,n=9, Brugada syndrome, n=1, arrhythmogenic right ventricular cardiomyopathy, n=2), with 60% of patients being
genotype positive. Primary indication for implantation of ILR included ongoing monitoring +/ symptoms (n=15, 75%), suspicion of
noncompliance (n=1, 5%), and liberalization of recommended activity restrictions (n=4, 25%). A total of 172 transmissions were
received in patients with inherited arrhythmia syndromes, with 7% yielding actionable data. The majority (52%) of symptom events
were documented in the long QT syndrome population, with only 1 tracing (5%) yielding actionable data. Automatic transmissions
were mostly seen in the catecholaminergic polymorphic ventricular tachycardia cohort (81%), with 21% yielding actionable data.
There was no actionable data in routine transmissions.
Conclusions-—ILRs in patients with suspected or conﬁrmed inherited arrhythmia syndromes may be useful for guiding
management. Findings escalated therapies in 30% of subjects. As importantly, in this high-risk population, the majority of symptom
events represented normal or benign rhythms, reassuring patients and physicians that no further intervention was required. ( J Am
Heart Assoc. 2016;5:e003632 doi:10.1161/JAHA.116.003632)
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O ver the last 2 decades, considerable progress has beenmade in the understanding of primary electrical disor-
ders leading to sudden cardiac death in children and young
adults. Many of these, including long QT syndrome, Brugada
syndrome (BrS), catecholaminergic polymorphic ventricular
tachycardia (CPVT), and arrhythmogenic right ventricular
cardiomyopathy are autosomal-dominant disorders collec-
tively referred to as the inherited arrhythmia syndromes (IAS).
Despite advancements in the diagnosis and understanding of
IAS, there remain diagnostic uncertainties and management
dilemmas.
Genetic testing can be deﬁnitive when a pathologic
mutation is identiﬁed in a patient with a typical clinical
history. However, the interpretation of mutations is not always
so clear. Speciﬁcally, as genetic testing is being utilized on a
wide scale, variants of unknown signiﬁcance are being
increasingly identiﬁed. Interpreting a novel mutation, or one
not previously linked causally to an IAS, particularly if the
clinical history suggests a low probability of having the
disease, poses a dilemma for the clinician, so-called “genetic
purgatory.”1
After a genetic diagnosis is made for a potentially lethal
inherited arrhythmia, considerable uncertainty remains
regarding the management and outcomes for an individual
From the Division of Pediatric Cardiology, Washington University School of
Medicine/Saint Louis Children’s Hospital, Saint Louis, MO (J.N.A.S., T.M.B.,
G.F.V.H.); Division of Pediatric Cardiology, Mercy Hospital, Saint Louis, MO
(B.I.B.); Pediatrix Cardiology, Springﬁeld, MO (F.K.E.).
An accompanying Table S1 is available at http://jaha.ahajournals.org/
content/5/6/e003632/DC1/embed/inline-supplementary-material-1.pdf
Correspondence to: Jennifer N. Avari Silva, MD, Washington University SOM,
1 Children’s Place, CB 8116 NWT, Saint Louis, MO 63110. E-mail:
silva_j@kids.wustl.edu
Received March 25, 2016; accepted May 2, 2016.
ª 2016 The Authors. Published on behalf of the American Heart Association,
Inc., by Wiley Blackwell. This is an open access article under the terms of the
Creative Commons Attribution-NonCommercial License, which permits use,
distribution and reproduction in any medium, provided the original work is
properly cited and is not used for commercial purposes.
DOI: 10.1161/JAHA.116.003632 Journal of the American Heart Association 1
ORIGINAL RESEARCH
 at Washington University on June 8, 2016http://jaha.ahajournals.org/Downloaded from 
patient. There is general agreement that a subpopulation of
phenotype-positive IAS patients (speciﬁcally long QT syn-
drome and CPVT patients) should receive b-blocker therapy.
However, clinicians must exercise clinical judgment when
negotiating activity restrictions while taking into account
guidelines for sports participation.2–5
The use of implantable loop recorders (ILRs) has been
reported in pediatric patients with infrequent syncope or
palpitations.6–8 In 2011, Kubala et al9 published their expe-
rience with the use of ILRs in 11 BrS patients where there was
clinical suspicion of ventricular arrhythmias. They identiﬁed
bradycardia and atrioventricular block during syncopal
episodes, but no ventricular arrhythmias.
In an effort to identify occult arrhythmias, as well as to
accurately assess cardiac rhythms during symptomatic
events, we have implanted ILRs in selected patients with a
documented or suspicious history for IAS. The intent of this
study is to categorize the ﬁndings of continuous ILR
monitoring and the impact it had on tailoring the management
of potentially life-threatening arrhythmias to individual
patients.
Methods
After obtaining approval from the Institutional Review Board at
Washington University School of Medicine, a retrospective
chart review was undertaken. Informed consent was waived
per Institutional Review Board approved protocol. Patients
who underwent ILR implantation with a known or suspected
diagnosis of an IAS from 2008 to 2015 were identiﬁed. IAS
diagnoses in this analysis included long QT syndrome, CPVT,
BrS, and arrhythmogenic right ventricular cardiomyopathy.
Patients who were not known or suspected IAS patients were
not included in the analysis. Data collected included catego-
rization of diagnosis, treatment, transmitted tracings, and the
impact of the ILR on patient management. Transmissions
were categorized as symptomatic (patient triggered), autotrig-
gered (device triggered), or routine, though transmission
could fall into >1 category. Transmission data were catego-
rized as “actionable” if the arrhythmia detected led directly to
a change of medical or device therapy. Patient-speciﬁc
programming of tachycardia and bradycardia zones was
performed at time of implant, taking into account patient
age, medications, and previous documented arrhythmia data
(when available).
Statistical Analysis
Results are predominantly descriptive ﬁndings and expressed




A total of 20 patients (11 males, 9 females) were implanted
with an ILR for conﬁrmed (n=11, 55%) or suspected (n=9,
45%) IAS: 10 with a Reveal ILR (2008–2013), and 10 with a
LINQ ILR (2014–2015). The average age at time of implant
was 12.53.6 years. Primary indication for implantation of
ILR included ongoing monitoring +/ symptoms (n=15, 75%)
suspicion of noncompliance (n=1, 5%), and liberalization of
guideline-recommended activity restrictions (n=4, 25%).
IAS diagnoses included long QT syndrome (n=8, 40%;
average QTc 466 ms), CPVT (n=9, 45%), arrhythmogenic right
ventricular cardiomyopathy (n=2, 10%), and BrS (n=1, 5%).
Genetic testing yielded 60% (n=9/15) genotype-positive and
40% (n=6/15) genotype-negative patients with no genetic
testing performed in 5 patients. Speciﬁcally, 6 patients had an
identiﬁed pathologic mutation (with 3 of the 6 patients having
compound mutations) and 3 patients with identiﬁed variants
of unknown signiﬁcance (Table 1).
Transmission Data
A total of 172 total transmissions were received, with an
average of 8.67 ILR downloads/patient. There were 12
transmissions (7%) yielding actionable data in 6 patients.
(Table 2).
In the LQT group, there were 58 total transmissions
(actionable data n=1, or 2%), in the CPVT group there were
100 transmissions (actionable data n=10, or 10%), in the
arrhythmogenic right ventricular cardiomyopathy group there
were 8 transmissions (actionable data n=1, or 13%) and lastly,
in the BrS group there were 6 transmissions (actionable data
n=0) (Table 2). The majority of actionable events, 10/12
(83%), occurred in patients with a diagnosis of CPVT.
A total of 33 transmissions were labeled by patients as
symptom episodes, including chest pain, syncope, dizziness,
palpitations, nausea, and seizure. Of the 33 symptom events,
3 (10%) had an actionable tracing resulting in change of
medication or device with the remaining 30 transmissions
(90%) demonstrating sinus rhythm/sinus tachycardia +/
premature ventricular contractions. Additionally, 42 automatic
transmissions were received with 8 (19%) transmissions
demonstrating actionable data, predominantly in the CPVT
population. The remaining 34 automatic transmissions (81%)
demonstrated sinus rhythm/sinus tachycardia and occasion-
ally isolated premature ventricular contractions. Nine trans-
missions were identiﬁed as both symptom and automatic
transmissions, with 1 of these transmissions (11%) yielding
actionable data. Eighty-eight routine transmissions were
downloaded with no actionable data in those transmissions
(Figure; Table S1).
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Outcomes/Current Status
There were no deaths in the patient cohort. At last follow-up,
ILRs were explanted in 6/20 (30%) of patients for device end of
life. A single patient with CPVT had the ILR upgraded to an
implantable cardioverter deﬁbrillator for symptomatic poly-
morphic ventricular tachycardia. There were no adverse events
associated with the device, including infection or erosion.
Discussion
This study represents the only study to date investigating the
utility of ILRs in pediatric patients across all inherited
arrhythmia syndromes. There are several novel ﬁndings from
this study. First, symptoms in this patient population do not
correlate well with arrhythmic events. Additionally, automatic
transmissions were important in detecting subclinical
arrhythmias. These data inﬂuenced clinical decision making
regarding medication titration, addition of medication, med-
ication compliance, and titrating activity levels. Lastly, vari-
ants of unknown signiﬁcance need to be interpreted carefully
in the context of the clinical picture and clinician index of
suspicion, which are important in guiding decision making.
Important implications arise from these ﬁndings. The long
QT syndrome patient cohort had the largest number of
symptoms transmissions (19 symptoms +/ automatic
transmissions/34 total transmissions, 56%) with only 1
symptom tracing (5%) leading to titration in medication
regimen. The remaining 95% of symptom events in the long
QT population were not associated with arrhythmia. Through
the entire cohort of patients, 90% of symptomatic transmis-
sions demonstrated normal sinus rhythm/sinus tachycardia
(74%) or minimal rhythm abnormalities such as isolated
premature ventricular contractions (16%). Given that the





Implant (y) Genetic Test Results Medical Therapy
1 LQTS 15.9 Negative None
2 LQTS 4.8 n/a None
3 LQTS 16.1 Negative Betaxolol
4 LQTS 11.7 Pathogenic mutation: KCNQ1—Ser566Phe
VUS: SNTA1—Arg336Trp
Nadolol
5 LQTS 10.7 Pathogenic mutation: KCNQ1—Arg366Trp Nadolol
6 LQTS 7.9 Negative None
7 LQTS 12 Negative Nadolol
8 LQTS 13 VUS: KCNH2—Ala913Val None
9 CPVT 18.3 n/a Noncompliant
10 CPVT 10.6 n/a Noncompliant
11 CPVT 13.2 VUS: RYR2—c.1465+4C>T, IVS15+4C>T Nadolol
12 CPVT 17.3 Negative Atenolol
13 CPVT 7.8 Pathogenic mutation: RYR2—Glu3987Lys Nadolol
14 CPVT 13.6 Pathogenic mutation: RYR2—Arg4959Gln Atenolol








17 CPVT 10.5 n/a Nadolol
18 ARVC 14.7 VUS: RYR2—Arg1013Gln Atenolol
19 ARVC 17.9 n/a None
20 BrS 7.6 Negative None
Patient data, including demographic data, clinical data, genetic diagnoses, indications for implant, and medical therapy are presented. ARVC indicates arrhythmogenic right ventricular
cardiomyopathy; BrS, Brugada syndrome; CPVT, catecholaminergic polymorphic ventricular tachycardia; ILR, implantable loop recorders; LQTS, long QT syndrome; n/a, not applicable;
VUS, variant of unknown signiﬁcance.
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majority of symptom-driven transmissions were not action-
able or lethal arrhythmias, symptoms are not reliable markers
for escalation of therapy or guidance around activity. Current
practices when caring for these children often includes
incorporating symptoms into risk stratiﬁcation algorithms. ILR
data demonstrate that symptoms in this population may not
be reliable surrogates for arrhythmia.
Identiﬁcation of occult arrhythmias is crucial to optimal
management of patients with known or suspected IAS. In fact,
19% of automatically recorded transmission contained data
that altered the patients’ medical course. Prior to the growing
use of ILRs in this population, the incidence of subclinical
arrhythmias in the IAS population was unknown. Perhaps
most concerning was the data collected from the CPVT
cohort, where 21% of automatic transmissions yielded
actionable data, implying signiﬁcant subclinical arrhythmia
prevalence in this population. Intelligent programming of the
ILR in this subpopulation is important in identifying these
occult arrhythmic events.
Patients with genetic mutations classiﬁed as variants of
unknown signiﬁcance are a growing clinical conundrum. In the
cohort presented, 5 patients had genetic variants of unknown
signiﬁcance with 3/5 patients (60%) having actionable
tracings. For patients with a documented variant of unknown
signiﬁcance, demonstration of polymorphic ventricular tachy-
cardia would swing the pendulum in the direction of







If Actionable Data, What Was
Rhythm and Resultant Action?
Symptom Events
(No. Transmissions)
If Symptom Event, What
Was the Rhythm?
1 LQTS None n/a Yes (3) NSR92; ST
2 LQTS None n/a Yes (1) ST
3 LQTS None n/a Yes (6) ST96
4 LQTS None n/a Yes (2) ST92
5 LQTS None n/a Yes (5) NSR95
6 LQTS None n/a None n/a
7 LQTS None n/a None n/a
8 LQTS Yes (1) Tightly coupled ventricular couplet→Activity
Restrictions
Yes (2) ST; Tightly coupled ventricular couplet
9 CPVT None n/a Yes (6) ST93; NSR w/ventricular bigeminy;
ST w/isolated PVCs92
10 CPVT None n/a Yes (2) ST92
11 CPVT None n/a Yes (1) ST
12 CPVT None n/a Yes (1) ST
13 CPVT Yes (2) Polymorphic VT→Initiate of b-blocker
AT→Uptitrate of b-blocker
None n/a
14 CPVT Yes (4) Sinus pauses, bidirectional ventricular coupletsaInitiate
atenolol
Nonsustained VT→Encourage medication compliance
Significant sinus pauses→Wean b-blockers
Polymorphic VT→Explant ILR; Implant ICD
Yes (1) TdP
15 CPVT Yes (1) Multifocal PVCs→Initiate nadolol Yes (2) ST; NSR w/ventricular trigeminy
16 CPVT Yes (3) Multifocal PVCs→Uptitrate nadolol
Bidirectional VT→Initiate Flecainide
Bidirectional Ventricular CoupletsaUptitrate flecainide
Yes (4) Bidirectional VT; NSR w/ventricular
bigeminy92; NSR w/isolated PVCs
17 CPVT None n/a None n/a
18 ARVC Yes (1) Sinus pause→Wean b-blocker Yes (1) ST
19 ARVC None n/a Yes (1) ST
20 BrS None n/a Yes (4) ST93; NSR
Both symptom and actionable data by patent are presented. Details about transmission data are provided. ARVC indicates arrhythmogenic right ventricular cardiomyopathy; AT, atrial
tachycardia; BrS, Brugada syndrome; CPVT, catecholaminergic polymorphic ventricular tachycardia; ICD, implantable cardioverter deﬁbrillator; ILR, ; LQTS, long QT syndrome; n/a, not
applicable; NSR, normal sinus rhythm; PVCs, premature ventricular contractions; ST, sinus tachycardia; TdP, Torsades de Pointes; VT, ventricular tachycardia.
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heightened individual treatment as well as cascade screening
of at-risk family members. These data give credence to clinical
index of suspicion weighing heavily in clinical decision
making.
Guidance around activity is an important part of the
ongoing management for these patients. In this cohort, ILRs
provided important data to guide in titration of activity level
with an acceptable level of risk. After shared decision making
A B
C D
Figure. The tracings shown were obtained from 4 different patients in the cohort. The tracing in (A) represents an ILR download from a patient
with genotype-positive catecholaminergic polymorphic ventricular tachycardia (CPVT). This event of polymorphic ventricular tachycardia
occurred with activity (running), but the patient was asymptomatic with this event. In response to this event, the patient was started on nadolol.
B, Represents a symptom event (chest pain) from a patient being treated with nadolol with genotype-positive CPVT. The tracing demonstrates
ventricular bigeminy followed by a bidirectional ventricular tachycardia, which then spontaneously terminates and returns to sinus rhythm with
ventricular bigeminy. In response to this event, the patient was admitted for initiation of ﬂecainide in addition to nadolol. C, Represents a patient
with genotype-positive CPVT who had a symptom event and a history of noncompliance with medication. This event of polymorphic ventricular
tachycardia occurred during a time of emotional stress. Following this download, the patient underwent implantation of an automatic
intracardiac deﬁbrillator. The patient tracing in (D) is from a symptom event (chest pain, near syncope) in a patient with long QT syndrome who
had just been jogging. He was being treated with betaxolol and was compliant with this medication. The tracing demonstrating sinus rhythm was
reassuring that there was not an arrhythmic component to his symptoms. ILR indicates implantable loop recorder.
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between clinician, patient, and family, and frank conversations
about risk, certain patients had liberalized activity guidance
with close monitoring by ILR with no documented arrhythmic
events. ILRs may be useful in allowing select patients to
reenter sports with intensive arrhythmia monitoring.
Lastly, 6/20 monitored patients (30%) had arrhythmias
identiﬁed that prompted interventions including activity
restriction, titration of medication, and implantable car-
dioverter deﬁbrillator implant. These data, which are critically
important in guiding patients regarding medical/device ther-
apy and activity restrictions, are increasingly available due to
the increased use of ILRs, likely due to lower threshold for
implantation. In fact, the newer generation LINQ ILR has the
advantage of being markedly (87%) smaller than the previous
generation as well as being quickly inserted subcutaneously,
thereby lowering the clinician’s threshold to recommend the
device.10 Our data support this trend as equal numbers of
devices (n=10) were implanted in the 5 years of the Reveal
device versus 2 years of the LINQ.
Study Limitations
This study, despite spanning 7 years, is limited by a small
sample size and therefore it is difﬁcult to draw statistically
signiﬁcant conclusions. Additionally, this is a retrospective
study design and is therefore has the associated biases of
retrospective studies. There are inherent limitations in data
collection, given programming limitations. Our practice has
been to tailor these parameters to be patient speciﬁc, taking
into account age, activity level, medications, and prior
arrhythmic data (when available). However, it is possible that
patients may experience ectopy that is slower or shorter than
the programmed tachycardia zone, which would therefore not
be recorded.
Conclusions
ILRs in patients with suspected or conﬁrmed IAS may be
useful for guiding management. Findings escalated therapies
in 30% of subjects. As importantly, in this high-risk population,
the majority of symptom events represented normal or benign
rhythms, reassuring patients and physicians that no further
intervention was required. Given the wealth of data ILRs
provide in these patients, perhaps ILRs should be considered
in all IAS patients who do not meet criteria for implantable
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LQTS Total, n=58 12 5 34
Actionable transmissions, n=1 1 0 0
CPVT Total, n=100 17 34 49
Actionable transmissions, n=10 3 7 0
ARVD Total, n=8 2 3 3
Actionable transmissions, n=1 0 1 0
BrS Total, n=6 4 0 2
Actionable transmissions, n=0 0 0 0
Total Total transmissions 42 42 88
Actionable transmissions, n=12 4 8 0
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Table S1:
Number of symptom, automatic and routine standard of 
care transmissions by disease substrate. CPVT = 
Catecholaminergic polymorphic ventricular tachycardia, 
LQTS = Long QT syndrome, BrS = Brugada syndrome, 
and ARVC = Arrhythmogenic right ventricular 
cardiomyopathy. 
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